Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14639362 | 0.65 | ALDH1A1 (0.36) | ALDH1A1MAPTATMMCL1 | |
| SCHEMBL13400618 | 0.65 | GSTP1 (0.33) | — | |
| SCHEMBL160163 | 0.65 | — | — | |
| SCHEMBL3200756 | 0.65 | — | — | |
| SCHEMBL21955629 | 0.64 | — | — | |
| SCHEMBL4657978 | 0.63 | ATM (0.50) | ALDH1A1MAPTATMMCL1CES2 | |
| SCHEMBL24612978 | 0.62 | POLB (0.32) | ALDH1A1MAPTATMMCL1 | |
| SCHEMBL1044726 | 0.62 | — | — | |
| SCHEMBL4195110 | 0.61 | — | — | |
| SCHEMBL3201257 | 0.60 | CYP1A2 (0.32) | ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279248-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE, LLC | 2016-09-29 | — | — | US | disclosed |
| US-9364554-B2 | Extracellular targeted drug conjugates | CENTROSE LLC (US) | 2016-06-14 | — | — | US | disclosed |
| US-8703723-B2 | Glycoside compounds and pharmaceutical compositions thereof | CENTROSE, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130178431-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | CENTROSE, LLC (US) | 2013-07-11 | — | — | US | disclosed |
| US-8470980-B2 | Extracellular targeted drug conjugates | CENTROSE, LLC (US) | 2013-06-25 | — | — | US | disclosed |
| US-8361973-B2 | Glycoside compounds and pharmaceutical compositions thereof | CENTROSE, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110319350-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | CENTROSE, LLC (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110064752-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE, LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-7732643-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7671226-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | HANAOKA HIDENORI | 2010-02-25 | — | — | US | disclosed |
| EP-1426379-B1 | TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | SUMITOMO CHEMICAL CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | HANAOKA HIDENORI | 2009-02-26 | — | — | US | disclosed |
| US-7439379-B2 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20040242410-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1426379-A1 | TRANSITION METAL COMPLEX,CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064752-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | FCGR2A, ENGASE, FCER2 | ALDH1A1 1232/4885MAPT 1818/4885ATM 3936/4885 |
| US-20090054607-A1 | Transition metal complex, catalyst for olefin polymerization, and process for producing olefin polymer with the same | C1R, C1S, AP1M1 | ALDH1A1 1229/4885MAPT 2641/4885ATM 3326/4885 |
| US-20100048933-A1 | TRANSITION METAL COMPLEX, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER WITH THE SAME | C1R, C1S, AP1M1 | ALDH1A1 1229/4885MAPT 2641/4885ATM 3326/4885 |
| US-20110319350-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | UGCG, NFATC1, GAA | ALDH1A1 1948/4885MAPT 3783/4885ATM 3295/4885 |
| US-20130178431-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | UGCG, NFATC1, GAA | ALDH1A1 1948/4885MAPT 3783/4885ATM 3295/4885 |
| US-20160279248-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | FCGR2A, ENGASE, FCER2 | ALDH1A1 1232/4885MAPT 1818/4885ATM 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.